Inxmed co. ltd
WebInxMed is a clinical-stage biotech company established in the end of 2024. The company dedicates on developing innovative therapies targeting stroma microenvironment and … Web9 mei 2024 · NANJING, China, May 8, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting …
Inxmed co. ltd
Did you know?
Web7 sep. 2024 · NANJING, China, Sept. 7, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates to developing innovative therapies targeting … WebInxmed Co. Ltd. has raised $50 million in a series B round to support clinical trials of its lead candidate, IN-10018, for the treatment of multiple cancers in both the U.S. and …
Web9 mei 2024 · InxMed is a clinical-stage biotech company established in the end of 2024. The company dedicates on developing innovative therapies targeting stroma … Web16 aug. 2024 · The FDA has granted a fast-track designation to IN10018, a selective ATP-competitive focal adhesion kinase (FAK) small molecule inhibitor, for the treatment of …
Web9 mrt. 2024 · Inxmed Co. Ltd. has raised $50 million in a series B round to support clinical trials of its lead candidate, IN-10018, for the treatment of multiple cancers in both the … Web30 mei 2024 · InxMed Co., Ltd is pleased to announce that the clinical data from an open-label phase Ib trial evaluating the efficacy and safety of IN10018, a highly potent and …
http://www.wxinmed.com/About.html
Web18 okt. 2024 · NANJING, China, Oct. 17, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting … ip route portWebInxMed (Hong Kong) Limited. InxMed (Hong Kong) Limited (CR No: 2347788) was incorporated on 11-MAR-2016 in Hong Kong. Their business is recorded as Private … ip route policyWebNANJING, China, May 9, 2024 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, today announced that it had completed $15 million in Series B+ Financing. The Series B+ was funded by Hyfinity Investments. 14 ip route printWebFounded in 2024 "Shanghai Refreshgene Therapeutics is a startup company focusing on AAV gene therapy and siRNA therapy." Description Source: VentureRadar Research / … ip route pollWebInxMed is a clinical-stage biotech company established in the end of 2024. The company dedicates on developing innovative therapies targeting stroma microenvironment and … ip route prohibitWeb18 okt. 2024 · InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, … ip route rtnetlink answers: file existsWeb8 sep. 2024 · InxMed Co., Ltd, a clinical-stage biotechnology company dedicates to developing innovative therapies targeting drug resistance and metastasis for hard-to … ip route print windows